Seeing breast cancer before it forms.
DatChem-Breast non-invasively predicts the risk of an asymptomatic woman developing breast cancer, identifying tissue in transition up to a decade ahead of current imaging.
Detecting tissue in transition.
Long before a tumour forms, or becomes visible to imaging or palpable to the hand, the chemistry of breast tissue begins to change.
DatChem-Breast reads that chemical signature directly from a standard MRI, identifying breast tissue in transition toward a cancer. It is a window on disease as it begins, not after it has formed.
- Non-invasive. No biopsy, no contrast, just chemistry, from a routine scan.
- Asymptomatic risk. Designed for women before any sign or symptom appears.
- A decade of warning. Identification up to ten years ahead of current methods.
The journey of a developing cancer.
Atypical ductal hyperplasia carries progressive genetic aberrations, and they are reflected independently in the tissue chemistry, long before a tumour forms. DatChem-Breast reads that chemistry and identifies the stages prior to a cancer developing.
Normal breast
Orderly, healthy tissue
Hyperplasia
Genetic aberrations begin
Carcinoma in situ
Contained, pre-invasive
Invasive cancer
Spreads into nearby tissue
Identifying when a cancer is imminent, enabling intervention before it becomes life threatening, not after.
Genomic view of cancer development after The Genomic and Biologic Landscapes of Breast Cancer, Int. J. Mol. Sci. 2024, 25(23), 13165. doi.org/10.3390/ijms252313165
What earlier knowledge makes possible.
Time to act
Earlier evaluation of treatment options, while there is still room to make considered decisions.
Her own control
Serial scanning makes risk personal, not statistical, each woman is measured against herself.
Empowered choice
Clear, objective information equips the woman to make the decisions that suit her.
From scan to report, on existing scanners.
DatChem-Breast adds a short sequence to a standard 3T MRI, no new hardware, with results returned to the physician in minutes.
Patient scan
A 15-minute scan in a 3T MRI captures the raw spectral data, no contrast, no biopsy.
Data capture
Raw data is transmitted securely from the scanner to the DatChem cloud, region by region.
Data processing
The chemical signature is extracted and compared against our exclusive databases.
Physician report
A report informs the statistical likelihood of disease and the treatment options.
DatChem-Breast is compatible and adaptable with other leading MRI platforms, including Philips and GE.
The longitudinal breast study, 2012–2024.
A pivotal validation study underpinning FDA, TGA and EMA regulatory approval, with each woman serving as her own control across repeat scans.
In the high-risk category, 32 of 33 cancers were correctly predicted, all on the very first scan.
DatChem's technologies are undergoing regulatory evaluation (TGA, FDA and EMA) and are not yet approved for routine clinical use in all markets.
Bring DatChem-Breast to your centre.
For clinical, research or partnership enquiries about DatChem-Breast, we'd be glad to hear from you.